Abeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

A number of other research firms also recently issued reports on ABEO. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research report on Monday, November 25th.

Abeona Therapeutics Trading Down 1.2 %

Shares of ABEO stock opened at $5.93 on Friday. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $257.78 million, a price-to-earnings ratio of -2.20 and a beta of 1.43. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01. The stock’s 50-day moving average price is $5.66 and its 200-day moving average price is $5.77.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in Abeona Therapeutics in the third quarter worth $84,000. Charles Schwab Investment Management Inc. bought a new stake in Abeona Therapeutics in the third quarter worth $151,000. XTX Topco Ltd bought a new stake in Abeona Therapeutics in the third quarter worth $160,000. Trexquant Investment LP bought a new stake in Abeona Therapeutics in the fourth quarter worth $382,000. Finally, JPMorgan Chase & Co. lifted its position in Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 28,606 shares during the last quarter. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.